HALIFAX, Nova Scotia, November 5, 2025 — Leads & Copy — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) has announced a non-brokered private placement to raise up to C$750,000.
The company plans to issue up to 30,000,000 units at $0.025 per unit. Each unit includes a Class A common share and one-half of a common share purchase warrant. Pending shareholder approval, each warrant allows the holder to buy a common share at C$0.05 for 36 months after the closing date.
The company intends to use the net proceeds for working capital and to fund the development of its product candidates. The private placement is subject to regulatory approvals, including approval from the Toronto Stock Exchange.
Closing is expected in November 2025. Finders will receive a cash fee of 8.0% of the gross proceeds, and broker warrants will allow the purchase of common shares.
All securities issued in the private placement will have a four-month statutory hold period.
Jenna McNeil, Communications Manager, JMcNeil@AppiliTherapeutics.com
Don Cilla, President and CEO, Info@AppiliTherapeutics.com
Source: Appili Therapeutics
